NEW YORK (GenomeWeb News) – Caliper Life Sciences today said that it has inked an OEM agreement with Access Genetics to market its LabChip GX microfluidic system for molecular diagnostic applications.
Under the agreement, Access Genetics will incorporate web-based software, materials, and protocols that it developed specifically for use with the LabChip GX and market the combined platform to clinicians, pathologists, and physicians. A Caliper spokesperson told GenomeWeb Daily News that the neither of the partners intend to seek US Food and Drug Administration clearance for the combined molecular diagnostic offering.
"Our partnership with Access Genetics should accelerate adoption of LabChip GX instruments in the attractive and evolving molecular diagnostic market," Caliper President and CEO Kevin Hrusovsky said in a statement.
Caliper sells the LabChip GX system, which uses microfluidic chip-based technology for nucleic acid analysis, for molecular diagnostic research purposes. The firm aims to further the LabChip GX's use in the molecular diagnostics field and is evaluating strategic options to achieve this goal, the Caliper spokesperson said.
Access Genetics has developed the TeleGene web-based software for molecular diagnostic applications. The Minneapolis-based firm also runs a CLIA and CAP-certified high complexity clinical laboratory.